GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

Rhea-AI Summary

GT Biopharma (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and CEO, will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5, 2026 in Toronto.

Format includes a presentation, panel discussion and one-on-one investor meetings; the company will be available for 1x1 meetings throughout the day (8:00 AM–5:00 PM EDT).

News Market Reaction

-1.42%

8 alerts

-1.42% News Effect

+18.8% Peak Tracked

-14.3% Trough Tracked

-$223K Valuation Impact

$16M Market Cap

0.9x Rel. Volume

On the day this news was published, GTBP declined 1.42%, reflecting a mild negative market reaction. Argus tracked a peak move of +18.8% during that session. Argus tracked a trough of -14.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $223K from the company's valuation, bringing the market cap to $16M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: March 5, 2026 Conference time window: 8:00 AM–5:00 PM EDT Conference edition: 9th Annual +5 more

8 metrics

Conference date March 5, 2026 Centurion One Capital 9th Annual Toronto Growth Conference

Conference time window 8:00 AM–5:00 PM EDT Presentation, panel and 1x1 investor meetings

Conference edition 9th Annual Centurion One Capital Toronto Growth Conference

Share price $0.4636 Pre-news trading level vs 52-week range

52-week high $3.85 Pre-news 52-week high level

52-week low $0.4011 Pre-news 52-week low level

Market cap $12,355,957 Pre-news equity valuation

20-day avg volume 1,373,380 shares Liquidity benchmark versus today’s volume

Market Reality Check

Price: $0.4884 Vol: Volume 605,749 vs 20-day ...

low vol

$0.4884 Last Close

Volume Volume 605,749 vs 20-day average 1,373,380 suggests muted trading interest pre-announcement. low

Technical Shares at $0.4636, well below the $1.37 200-day MA and 87.96% under the 52-week high.

Peers on Argus

GTBP was modestly lower ahead of this neutral conference update, while several b...

1 Down

GTBP was modestly lower ahead of this neutral conference update, while several biotech peers such as LIPO and SLRX showed strong gains and others like SCNI and VRAX were mildly positive. Momentum scanner activity captured only PBM moving down, indicating stock-specific rather than sector-wide trading.

Historical Context

5 past events · Latest: Feb 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 03	IND clearance	Positive	+2.3%	FDA cleared IND for GTB-5550 enabling Phase 1 solid tumor trial.
Jan 15	IND submission	Positive	+10.6%	Submitted IND for GTB-5550 with planned Phase 1 basket trial.
Nov 19	Pipeline update	Positive	+3.7%	Outlined progress on GTB-3650, GTB-5550, and GTB-7550 programs.
Nov 14	Earnings & update	Neutral	+26.1%	Reported Q3 2025 results with cash, expenses, and trial timelines.
Oct 23	Trial safety update	Positive	+9.0%	Phase 1 GTB-3650 advanced after no safety issues in Cohort 3.

Pattern Detected

Recent clinical, regulatory, and financing milestones often coincided with positive next-day price reactions.

Recent Company History

Over the last few months, GT Biopharma has focused on advancing its TriKE® NK cell engager pipeline and shoring up its capital structure. Key items included FDA IND clearance for GTB‑5550 with cash projected through Q4 2026, earlier GTB‑5550 IND submission plans, and multiple GTB‑3650 Phase 1 updates showing no major safety issues. Q3 2025 results highlighted low cash and going‑concern language. Against that backdrop, this conference appearance mainly reinforces visibility rather than adding new clinical or financial data.

Market Pulse Summary

This announcement highlights GT Biopharma’s participation in a growth conference on March 5, 2026, p...

Analysis

This announcement highlights GT Biopharma’s participation in a growth conference on March 5, 2026, providing additional exposure for its TriKE® NK cell engager platform and an opportunity for 1x1 investor meetings. Recent history centers on progressing GTB‑3650 and GTB‑5550 through early clinical stages while managing limited cash and going‑concern disclosures. Investors may focus on upcoming trial updates, financing developments, and progress toward resolving Nasdaq listing deficiencies.

Key Terms

immuno-oncology, natural killer (NK) cell, investor meetings

3 terms

immuno-oncology medical

"a clinical stage immuno-oncology company focused on developing innovative therapeutics"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

natural killer (NK) cell medical

"TriKE® natural killer (NK) cell engager platform"

A natural killer (NK) cell is a type of white blood cell in the immune system that acts like a rapid-response security guard, identifying and destroying infected or cancerous cells without prior training. For investors, NK cells matter because therapies or tests that harness, enhance, or measure them are central to many cancer and infectious disease treatments; progress or setbacks in NK-related products can affect clinical trial outcomes, regulatory decisions, and the commercial value of biotech firms.

investor meetings financial

"panel discussion and 1x1 investor meetingsPresentation Date"

Investor meetings are scheduled conversations or presentations where company leaders share financial results, strategy, forecasts and answer questions from current or potential investors and analysts. They matter because they give outsiders direct insight into a company’s performance and plans—like attending a progress review or Q&A—helping investors judge management’s competence, update expectations, and decide whether to buy, hold or sell shares.

AI-generated analysis. Not financial advice.

SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5^th, 2026, in Toronto, Ontario.

Centurion One Capital 9^th Annual Toronto Growth Conference

Format: Presentation, panel discussion and 1x1 investor meetings
Presentation Date: Thursday, March 5^th, 2026
Time: 8:00 AM EDT – 5:00 PM EDT

The Company will be available for one-on-one meetings at the conference. If interested, please contact your Centurion One Capital representative.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE^® NK cell engager platform. Our TriKE^® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE^® technology. For more information, please visit gtbiopharma.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.

TriKE^® is a registered trademark owned by GT Biopharma, Inc.

Investor Relations Contact:

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577

LinkedIn |Facebook |X |Instagram | YouTube

FAQ

When will GT Biopharma (GTBP) present at the Centurion One Capital Toronto Growth Conference?

GT Biopharma will present on Thursday, March 5, 2026. According to the company, Michael Breen will participate in a presentation, panel discussion and be available for one-on-one investor meetings between 8:00 AM and 5:00 PM EDT.

What will GT Biopharma (GTBP) discuss at the March 5, 2026 conference?

GT Biopharma will discuss its clinical-stage TriKE natural killer cell engager platform and company progress. According to the company, the event format includes a presentation, panel discussion and scheduled one-on-one investor meetings for detailed investor engagement.

Who from GT Biopharma (GTBP) will attend the Toronto Growth Conference on March 5, 2026?

Michael Breen, Executive Chairman and CEO, will attend and represent the company. According to the company, he will take part in a presentation, a panel discussion and be available for investor one-on-one meetings during the conference.

How can investors schedule a one-on-one meeting with GT Biopharma (GTBP) at the March 5, 2026 conference?

Investors should contact their Centurion One Capital representative to request meetings. According to the company, GT Biopharma will be available for one-on-one investor meetings throughout the conference day and meetings are arranged via Centurion One Capital.

What is the format and schedule for GT Biopharma's (GTBP) participation on March 5, 2026?

The company will participate in a presentation, panel discussion and one-on-one meetings from 8:00 AM to 5:00 PM EDT. According to the company, this schedule covers its investor-facing activities for the Centurion One Capital Toronto conference.

Will GT Biopharma (GTBP) provide clinical updates at the Centurion One Capital Toronto Growth Conference?

The company indicated participation in investor-focused sessions but did not specify detailed clinical readouts. According to the company, the session format allows for presentation and one-on-one meetings where management can discuss clinical-stage TriKE platform developments with investors.